FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like DxTerity Collaborates With On The Development Of A Cancer Genomic Blood Test To Predict Response To Radiation Therapy September 21, 2017 Elekta Radiosurgery Solutions Highlighted At May 25, 2017 Big Names in Biotech Seek $1M to Build Life-Size Statue of Legend Henri Termeer January 24, 2018
DxTerity Collaborates With On The Development Of A Cancer Genomic Blood Test To Predict Response To Radiation Therapy September 21, 2017
